Vanguard Investments Australia’s Sionna Therapeutics SION Stock Holding History

Vanguard Investments Australia’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154K	Buy	+3,490	New	+$140K	﹤0.01%	2215

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Investments Australia's SION Position: Q2 2026 in Review

Vanguard Investments Australia opened a new position in Sionna Therapeutics (SION) in Q2 2026: 3,490 shares worth $154K. The stake represents ﹤0.01% of the portfolio and ranks #2215 among its holdings.

132 funds tracked by Wall St. Rank hold SION as of Q2 2026.

Vanguard Investments Australia held 3,490 shares of Sionna Therapeutics worth $154K as of Q2 2026.
Sionna Therapeutics was a new Vanguard Investments Australia position in Q2 2026.
Sionna Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2215 holding.
132 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.